Clinical Trials Browser

Phase 3 × pyrotinib × 90 days × Clear all

NCT06144944 2026-01-30

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT04447118 2025-12-19

PYRAMID-1

Phase 3 Completed

Non-squamous NSCLC